This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneerson, R Articles by Lagergard, T Search for Related Content PubMed PubMed Citation Articles by Schneerson, R Articles by Lagergard, T

 Previous Article  |  Next Article 

Infect Immun. 1992 September; 60(9): 3528-3532

Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.

Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.

ABSTRACT

Type 14 is one of the common types isolated from patients of all ages with infections caused by Streptococcus pneumoniae. Its capsular polysaccharide (Pn14) is composed of a neutrally charged tetrasaccharide repeat unit. Pn14 does not elicit protective levels of antibodies in infants and children and is a less than optimal immunogen of the 23-valent vaccine for adults. Pertussis toxin (PT) is both a virulence factor and protective antigen of Bordetella pertussis: it is not soluble at neutral pH and forms insoluble complexes with acidic polysaccharides. Both Pn14 and PT are potential components of vaccines for infants and children. Accordingly, a synthetic scheme was devised to prepare a conjugate of Pn14 and PT. An adipic acid hydrazide derivative of Pn14 was bound to PT at pH 3.9 by carbodiimide-mediated condensation. The conjugation procedure inactivated the PT as assayed by CHO cell and histamine-sensitizing activity. The Pn14-PT conjugate elicited antibodies in mice to Pn14 at levels estimated to be protective in humans and elicited neutralizing antibodies to PT. We plan to evaluate Pn14-PT clinically.

This article has been cited by other articles:

• Pavliakova, D., Moncrief, J. S., Lyerly, D. M., Schiffman, G., Bryla, D. A., Robbins, J. B., Schneerson, R. (2000). Clostridium difficile Recombinant Toxin A Repeating Units as a Carrier Protein for Conjugate Vaccines: Studies of Pneumococcal Type 14, Escherichia coli K1, and Shigella flexneri Type 2a Polysaccharides in Mice. Infect. Immun. 68: 2161-2166 [Abstract] [Full Text]  
• Wright, A. C., Powell, J. L., Tanner, M. K., Ensor, L. A., Karpas, A. B., Morris, J. G. Jr., Sztein, M. B. (1999). Differential Expression of Vibrio vulnificus Capsular Polysaccharide. Infect. Immun. 67: 2250-2257 [Abstract] [Full Text]  
• Laferriere, C. A., Sood, R. K., de Muys, J.-M., Michon, F., Jennings, H. J. (1998). Streptococcus pneumoniae Type 14 Polysaccharide-Conjugate Vaccines: Length Stabilization of Opsonophagocytic Conformational Polysaccharide Epitopes. Infect. Immun. 66: 2441-2446 [Abstract] [Full Text]  
• Siber, G. (1994). Pneumococcal disease: prospects for a new generation of vaccines. Science 265: 1385-1387